Osteoporosis is a chronic condition characterized by low bone density and deterioration of bone tissue. Several factors such as age, gender, genetics, and lifestyle choices can contribute to the development of osteoporosis.
{"title":"Aggravating factors for osteoporosis; a brief overview of the current findings","authors":"M. Zahmatkesh","doi":"10.34172/jpd.2023.11214","DOIUrl":"https://doi.org/10.34172/jpd.2023.11214","url":null,"abstract":"Osteoporosis is a chronic condition characterized by low bone density and deterioration of bone tissue. Several factors such as age, gender, genetics, and lifestyle choices can contribute to the development of osteoporosis.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"463 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75125851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nephrolithiasis is one of the common diseases without effective treatment, the incidence of which has increased in the world in recent decades. Sodium-glucose co-transporter 2 inhibitor can reduce the probability of nephrolithiasis in diabetic and non-diabetic people.
{"title":"Pharmacological effect of sodium-glucose cotransporter 2 inhibitors in reducing the incidence of nephrolithiasis","authors":"Arash Najafian, Sadaf Esteki","doi":"10.34172/jpd.2023.11220","DOIUrl":"https://doi.org/10.34172/jpd.2023.11220","url":null,"abstract":"Nephrolithiasis is one of the common diseases without effective treatment, the incidence of which has increased in the world in recent decades. Sodium-glucose co-transporter 2 inhibitor can reduce the probability of nephrolithiasis in diabetic and non-diabetic people.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"150 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79456522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Bahadoram, B. Keikhaei, M. Davoodi, Najmeh Nameh Goshay Fard, Pouria Ghiasi, E. Akade
Thalassemia is a hematological disorder caused by a gene mutation that leads to defective synthesis of hemoglobin complex. One of the complications of thalassemia is hypocalcemia which is presented with paresthesia, muscle spasm, low-serum calcium, and intracranial calcification. Hypocalcemia can affect thalassemic patients via various mechanisms. Blood transfusion-related and transfusion-independent iron overload, drug side effects, vitamin D3 deficiency, and genetic disorders and polymorphisms are among the etiologies of hypocalcemia in major thalassemia. A careful approach to the differential etiology of this phenomenon is crucial for a resultful treatment.
{"title":"Hypocalcemia in thalassemia major patients requires an extra-careful approach","authors":"M. Bahadoram, B. Keikhaei, M. Davoodi, Najmeh Nameh Goshay Fard, Pouria Ghiasi, E. Akade","doi":"10.34172/jpd.2023.11203","DOIUrl":"https://doi.org/10.34172/jpd.2023.11203","url":null,"abstract":"Thalassemia is a hematological disorder caused by a gene mutation that leads to defective synthesis of hemoglobin complex. One of the complications of thalassemia is hypocalcemia which is presented with paresthesia, muscle spasm, low-serum calcium, and intracranial calcification. Hypocalcemia can affect thalassemic patients via various mechanisms. Blood transfusion-related and transfusion-independent iron overload, drug side effects, vitamin D3 deficiency, and genetic disorders and polymorphisms are among the etiologies of hypocalcemia in major thalassemia. A careful approach to the differential etiology of this phenomenon is crucial for a resultful treatment.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88143509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Mocka, S. Ferraro, M. Ardini, M. Marchini, Laura Panaro, M. Trezzi, D. Rolla
Kidney transplant recipients (KTR) have a higher risk of developing malignancies compared to the general population, due to the immunosuppressive regimens which can promote the oncogenesis process. The incidence of de novo non-melanoma skin cancer (NMSC) in KTR is greater than in the general population. Basal cell carcinoma (BCC) represents one of the most frequent malignancies in KTR. Sonidegib is a Hedgehog signaling pathway inhibitor approved for the treatment of locally advanced basal-cell carcinoma (LABCC) that following surgery or radiation therapy, or is given to those candidates who are not eligible to surgery or radiation therapy. This paper reports the case of a kidney transplant patient, who developed severe acute kidney injury (AKI) due to rhabdomyolysis (RML) induced by sonidegib therapy which required renal replacement therapy (RRT).
{"title":"Sonidegib induced rhabdomyolysis in kidney transplant patient: a case report","authors":"S. Mocka, S. Ferraro, M. Ardini, M. Marchini, Laura Panaro, M. Trezzi, D. Rolla","doi":"10.34172/jpd.2023.11204","DOIUrl":"https://doi.org/10.34172/jpd.2023.11204","url":null,"abstract":"Kidney transplant recipients (KTR) have a higher risk of developing malignancies compared to the general population, due to the immunosuppressive regimens which can promote the oncogenesis process. The incidence of de novo non-melanoma skin cancer (NMSC) in KTR is greater than in the general population. Basal cell carcinoma (BCC) represents one of the most frequent malignancies in KTR. Sonidegib is a Hedgehog signaling pathway inhibitor approved for the treatment of locally advanced basal-cell carcinoma (LABCC) that following surgery or radiation therapy, or is given to those candidates who are not eligible to surgery or radiation therapy. This paper reports the case of a kidney transplant patient, who developed severe acute kidney injury (AKI) due to rhabdomyolysis (RML) induced by sonidegib therapy which required renal replacement therapy (RRT).","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87199821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Implication for health policy/practice/research/medical education: Brown tumors are uncommon in general (around 0.1%), however they tend to be more common in people with primary and secondary hyperparathyroidism.
{"title":"Brown tumor in hyperparathyroidism; a new look at an old problem","authors":"S. Toumaj","doi":"10.34172/jpd.2023.11207","DOIUrl":"https://doi.org/10.34172/jpd.2023.11207","url":null,"abstract":"Implication for health policy/practice/research/medical education: Brown tumors are uncommon in general (around 0.1%), however they tend to be more common in people with primary and secondary hyperparathyroidism.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89532767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyperparathyroidism (HPT) is one of the most common endocrine disorders, however it is a rare disease during pregnancy with notable maternal and fetal morbidity and mortality. We investigated 46 articles in PubMed database that seven articles focused on this topic. This review will examine the maternal and neonatal complications and the options for managing and treating this disease during pregnancy.
{"title":"Hyperparathyroidism during pregnancy, a mini review to complications and treatments","authors":"Fateme Sharafeddin, Golnaz Goudarzi","doi":"10.34172/jpd.2023.11210","DOIUrl":"https://doi.org/10.34172/jpd.2023.11210","url":null,"abstract":"Hyperparathyroidism (HPT) is one of the most common endocrine disorders, however it is a rare disease during pregnancy with notable maternal and fetal morbidity and mortality. We investigated 46 articles in PubMed database that seven articles focused on this topic. This review will examine the maternal and neonatal complications and the options for managing and treating this disease during pregnancy.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83370571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saeed Mardani, H. Mardanparvar, M. Momenzadeh, Seyedeh Fatameh Nourbakhsh Rezaiee, Mohammad-Reza Hajian
Introduction: Hypertension is one of the most common diseases and is the main cause of disability and mortality worldwide. Hyperuricemia has been recognized as one of the main causes of hypertension; however, few studies have been conducted to determine the correlation between serum uric acid reduction and blood pressure changes. Objective: This study aimed to assess the correlation between serum uric acid-reduction and blood pressure changes in a group of hemodialysis patients. Patients and Methods: This descriptive-analytical study was conducted on 21 hemodialysis patients taking allopurinol for the first time. Serum uric acid, systolic blood pressure, and diastolic blood pressure were measured before taking allopurinol, then patients were followed for two months, and these parameters were remeasured. Data were collected and the correlation between serum uric acid-reduction and blood pressure changes was evaluated. Results: Most patients were female, with a mean age of 56.81 ± 15.59 years. Results showed that the correlation between serum uric acid reduction and blood pressure changes was statistically significant with a ratio of 3.6 reduction for systolic blood pressure and 2.17 for diastolic blood pressure per one unit of uric acid reduction (P<0.05). Conclusion: Uric acid reduction is correlated with blood pressure reduction with both systolic and diastolic blood pressures.
{"title":"Serum uric acid-reduction and blood pressure changes in allopurinol administered hemodialysis patients; a pilot study","authors":"Saeed Mardani, H. Mardanparvar, M. Momenzadeh, Seyedeh Fatameh Nourbakhsh Rezaiee, Mohammad-Reza Hajian","doi":"10.34172/jpd.2023.11202","DOIUrl":"https://doi.org/10.34172/jpd.2023.11202","url":null,"abstract":"Introduction: Hypertension is one of the most common diseases and is the main cause of disability and mortality worldwide. Hyperuricemia has been recognized as one of the main causes of hypertension; however, few studies have been conducted to determine the correlation between serum uric acid reduction and blood pressure changes. Objective: This study aimed to assess the correlation between serum uric acid-reduction and blood pressure changes in a group of hemodialysis patients. Patients and Methods: This descriptive-analytical study was conducted on 21 hemodialysis patients taking allopurinol for the first time. Serum uric acid, systolic blood pressure, and diastolic blood pressure were measured before taking allopurinol, then patients were followed for two months, and these parameters were remeasured. Data were collected and the correlation between serum uric acid-reduction and blood pressure changes was evaluated. Results: Most patients were female, with a mean age of 56.81 ± 15.59 years. Results showed that the correlation between serum uric acid reduction and blood pressure changes was statistically significant with a ratio of 3.6 reduction for systolic blood pressure and 2.17 for diastolic blood pressure per one unit of uric acid reduction (P<0.05). Conclusion: Uric acid reduction is correlated with blood pressure reduction with both systolic and diastolic blood pressures.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78534868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Jafari, Ali Rastegar-Kashkouli, Pourya Yousefi, Ashkan Khavaran, Mohammad Sharifi, A. Baradaran, P. Yousefi, Dordaneh Rastegar
Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by elevated or inappropriately parathormone levels. The most common cause of PHPT is solitary parathyroid adenoma (80-85%). Parathyroid surgery generally encompasses symptomatic PHPT and asymptomatic patients who meet the surgical guideline criteria. If surgery is contraindicated, several non-surgical ablative techniques can be conducted to eliminate the pathological parathyroid tissue, which causes tissue necrosis in the affected gland. This review aims to look into the most recent studies on the efficacy of percutaneous ethanol injection therapy (PEIT), laser ablation (LA), radiofrequency ablation (RFA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU) in treatment of PHPT and analyze their application prospects. PEIT is a classic method that is less commonly used nowadays. The analysis of thermal ablation methods revealed that LA is inefficient and requires considerable repetition. Meanwhile, the MWA and RFA have a cure rate of over 85% and fewer complications; it seems that they have the potential to replace surgical methods in the future.
{"title":"Current status and perspectives of ultrasound-guided ablation techniques in patients with primary hyperparathyroidism","authors":"M. Jafari, Ali Rastegar-Kashkouli, Pourya Yousefi, Ashkan Khavaran, Mohammad Sharifi, A. Baradaran, P. Yousefi, Dordaneh Rastegar","doi":"10.34172/jpd.2023.11199","DOIUrl":"https://doi.org/10.34172/jpd.2023.11199","url":null,"abstract":"Primary hyperparathyroidism (PHPT) is an endocrine disorder characterized by elevated or inappropriately parathormone levels. The most common cause of PHPT is solitary parathyroid adenoma (80-85%). Parathyroid surgery generally encompasses symptomatic PHPT and asymptomatic patients who meet the surgical guideline criteria. If surgery is contraindicated, several non-surgical ablative techniques can be conducted to eliminate the pathological parathyroid tissue, which causes tissue necrosis in the affected gland. This review aims to look into the most recent studies on the efficacy of percutaneous ethanol injection therapy (PEIT), laser ablation (LA), radiofrequency ablation (RFA), microwave ablation (MWA), and high-intensity focused ultrasound (HIFU) in treatment of PHPT and analyze their application prospects. PEIT is a classic method that is less commonly used nowadays. The analysis of thermal ablation methods revealed that LA is inefficient and requires considerable repetition. Meanwhile, the MWA and RFA have a cure rate of over 85% and fewer complications; it seems that they have the potential to replace surgical methods in the future.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85799722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neda Arabizadeh, Danial Zakerzadeh, Reza Nakhaie, Mohammad Amin Alinejad, Pouria Barati, Abolfazl Samiei, Mohammad Mahdi Darvishi, H. Nasri, Ayda Hasanpour Dehkordi
Implication for health policy/practice/research/medical education: The brown tumor is a rare benign tumor developed by autonomous osteoclastic activity in hyperparathyroidism. In this photo-clinic, we present a 36-year-old man on chronic hemodialysis presented with a jaw mass. Radiography of the mandible showed a soft tissue mass lesion. Neck computed tomography showed a lytic lesion. A needle biopsy of the mandible showed a lobular design comprised of groups and clusters of osteoclast-like multinucleated giant cells, hemorrhage, and hemosiderin deposits and vascular fibroblastic stroma that were indicative of the brown tumor. Please
{"title":"The pathology of brown tumor in a-36-year-old man on maintenance hemodialysis","authors":"Neda Arabizadeh, Danial Zakerzadeh, Reza Nakhaie, Mohammad Amin Alinejad, Pouria Barati, Abolfazl Samiei, Mohammad Mahdi Darvishi, H. Nasri, Ayda Hasanpour Dehkordi","doi":"10.34172/jpd.2023.11200","DOIUrl":"https://doi.org/10.34172/jpd.2023.11200","url":null,"abstract":"Implication for health policy/practice/research/medical education: The brown tumor is a rare benign tumor developed by autonomous osteoclastic activity in hyperparathyroidism. In this photo-clinic, we present a 36-year-old man on chronic hemodialysis presented with a jaw mass. Radiography of the mandible showed a soft tissue mass lesion. Neck computed tomography showed a lytic lesion. A needle biopsy of the mandible showed a lobular design comprised of groups and clusters of osteoclast-like multinucleated giant cells, hemorrhage, and hemosiderin deposits and vascular fibroblastic stroma that were indicative of the brown tumor. Please","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78976502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatemeh Kafi, Pourya Yousefi, Sina Bakhshaei, Alireza Pouramini, Bina Bakhshaei, SriVaibhav Reddy, Krishina Theja Reddy
Cardiovascular disease (CVD) is one of the leading causes of mortality and morbidity worldwide. Several studies highlighted the association of CVD with hyperuricemia. We searched PubMed, EMBASE, Scopus, and DOAJ with the following keywords, including hyperuricemia and cardiovascular disease, to address these topics: 1) mechanism of hyperuricemia 2) relationship of hyperuricemia with cardiovascular disease 3) Treatment of hyperuricemia
{"title":"Role of hyperuricemia in cardiovascular disease and its treatment options: A review article","authors":"Fatemeh Kafi, Pourya Yousefi, Sina Bakhshaei, Alireza Pouramini, Bina Bakhshaei, SriVaibhav Reddy, Krishina Theja Reddy","doi":"10.34172/jpd.2023.11174","DOIUrl":"https://doi.org/10.34172/jpd.2023.11174","url":null,"abstract":"Cardiovascular disease (CVD) is one of the leading causes of mortality and morbidity worldwide. Several studies highlighted the association of CVD with hyperuricemia. We searched PubMed, EMBASE, Scopus, and DOAJ with the following keywords, including hyperuricemia and cardiovascular disease, to address these topics: 1) mechanism of hyperuricemia 2) relationship of hyperuricemia with cardiovascular disease 3) Treatment of hyperuricemia","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"299 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91461394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：